Reserve Forces Policy Board until its next meeting. The Designated Federal Officer will review all timely submitted written statements and provide copies to all the committee members before the meeting that is the subject of this notice.


Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.

[FR Doc. 2012–20416 Filed 8–17–12; 8:45 am]

DEPARTMENT OF DEFENSE
Office of the Secretary

Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting

AGENCY: Department of Defense, Office of the Under Secretary of Defense (Acquisition, Technology and Logistics).

ACTION: Federal advisory committee meeting notice.

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 1972 (5 U.S.C., Appendix, as amended) and the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended) the Department of Defense announces the following Federal advisory committee meeting of the Threat Reduction Advisory Committee (hereafter referred to as “the Committee”).

DATES: Thursday, September 6, 2012, from 8:30 a.m. to 5 p.m. and Friday, September 7, 2012, from 8:30 a.m. to 3 p.m.


FOR FURTHER INFORMATION CONTACT: Mr. William Hostyn, GS–15, DoD, Defense Threat Reduction Agency/J/2/5/8R, 8725 John J. Kingman Road, MS 6201, Fort Belvoir, VA 22060–6201. Email: william.hostyn@dtra.mil. Phone: (703) 767–4453. Fax: (703) 767–4206.

Written Statements: Pursuant to 102–3.155, the Department of Defense (DoD) announces the following Federal Advisory Committee Meeting of the Uniform Formulary Advisory Panel (hereafter referred to as the Panel).

DATES: September 27, 2012, from 9 a.m. to 1 p.m.

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: CDR Joseph Lawrence, DFO, Uniform Formulary Beneficiary Advisory Panel, 4130 Stanley Road, Suite 208, Building 1000 San Antonio, TX 78234–6012, Telephone: (210) 295–1271, Fax: (210) 295–2789, Email Address: Baprequests@tricare.osd.mil.

SUPPLEMENTARY INFORMATION:

Meeting Agenda:
1. Sign-In.
2. Welcome and Opening Remarks.
3. Public Citizen Comments.
4. Scheduled Therapeutic Class Reviews (Comments will follow each agenda item).
   a. Androgens-Anabolic Steroids.
   b. Antiocoagulants.
   c. Designated Newly Approved Drugs in Already-Reviewed Classes.
5. Panel Discussions and Vote.

Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102–3.140 through 102–3.165, and the availability of space, this meeting is open to the public. Seating is limited and will be provided only to the first 220 people signing-in. All persons must sign-in legibly.

Administrative Work Meeting: Prior to the public meeting, the Panel will conduct an Administrative Work Meeting.